Latigo Biotherapeutics (NASDAQ:LTGO) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Latigo Biotherapeutics (NASDAQ:LTGO) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

LTGO has been the topic of several other reports. Guggenheim started coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price objective on the stock. The Goldman Sachs Group assumed coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $73.00 target price for the company. Leerink Partners began coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued an “outperform” rating and a $36.00 target price for the company. Finally, Jefferies Financial Group began coverage on Latigo Biotherapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price target for the company. Four analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $52.25.

Latigo Biotherapeutics Stock Performance

Shares of NASDAQ LTGO opened at $14.30 on Friday. The business has a 50 day moving average price of $19.78. Latigo Biotherapeutics has a 52-week low of $13.50 and a 52-week high of $25.93.

Latigo Biotherapeutics (NASDAQ:LTGO) last announced its quarterly earnings results on Thursday, September 3rd. The company reported ($27.59) earnings per share for the quarter.

Insider Buying and Selling at Latigo Biotherapeutics

In other news, Director James B. Tananbaum acquired 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the transaction, the director owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Foresite Capital Management V, bought 140,000 shares of the stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the acquisition, the insider owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their position. The SEC filing for this purchase provides additional information.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing non-opioid treatments for acute and chronic pain. The company’s research centers on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of creating therapies that may provide pain relief without the risks associated with opioid medicines.

Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, including LTG-001, an investigational candidate being evaluated for pain-related conditions.